Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics
RANI Price/Volume Stats
| Current price | $0.53 | 52-week high | $5.38 |
| Prev. close | $0.56 | 52-week low | $0.46 |
| Day low | $0.52 | Volume | 327,400 |
| Day high | $0.56 | Avg. volume | 723,429 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $1.72 | Market Cap | 30.40M |
RANI Stock Price Chart Interactive Chart >
Rani Therapeutics Holdings, Inc. (RANI) Company Bio
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
RANI Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RANI Price Returns
| 1-mo | -36.75% |
| 3-mo | -66.03% |
| 6-mo | -72.54% |
| 1-year | -88.30% |
| 3-year | -94.43% |
| 5-year | N/A |
| YTD | -61.31% |
| 2024 | -58.73% |
| 2023 | -43.73% |
| 2022 | -63.91% |
| 2021 | N/A |
| 2020 | N/A |